Patents by Inventor Jonathan A. Winger
Jonathan A. Winger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165197Abstract: Described herein are methods for treating cardiovascular and pulmonary conditions, e.g., those associated with hypoxia, or treating a subject undergoing cardiac or respiratory arrest or cardiopulmonary resuscitation, using an H-NOX protein (or a mixture of H-NOX proteins), or using a combination of an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine). Also described are compositions comprising an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine).Type: ApplicationFiled: September 28, 2023Publication date: May 23, 2024Inventors: Stephen P.L. Cary, Natacha Le Moan, Ana Krtolica, Jonathan A. Winger
-
Publication number: 20220160823Abstract: The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1?) pathways and non-HIF-1? pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.Type: ApplicationFiled: December 10, 2021Publication date: May 26, 2022Inventors: Stephen P. L. CARY, Ana KRTOLICA, Natacha LE MOAN, Jonathan A. WINGER, Kevin G. LEONG
-
Publication number: 20210260155Abstract: Described herein are methods for treating cardiovascular and pulmonary conditions, e.g., those associated with hypoxia, or treating a subject undergoing cardiac or respiratory arrest or cardiopulmonary resuscitation, using an H-NOX protein (or a mixture of H-NOX proteins), or using a combination of an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine). Also described are compositions comprising an H-NOX protein (or a mixture of H-NOX proteins) and a catecholamine (such as epinephrine or norepinephrine).Type: ApplicationFiled: February 12, 2021Publication date: August 26, 2021Inventors: Stephen P.L. Cary, Natacha Le Moan, Ana Krtolica, Jonathan A. Winger
-
Patent number: 10202428Abstract: H—NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H—NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H—NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H—NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: October 12, 2016Date of Patent: February 12, 2019Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20180243364Abstract: The invention provides methods to modulate hypoxia-mediated tumor immunity by administration of an O2 carrier polypeptide (e.g., an H-NOX protein). The methods of the invention target both hypoxia inducible factor 1 alpha (HIF-1?) pathways and non-HIF-1? pathways of tumor immunity. Such methods are useful in the treatment of a wide variety of cancers and may be used alone or in combination with other anti-cancer therapies.Type: ApplicationFiled: March 17, 2016Publication date: August 30, 2018Inventors: Stephen P. L. CARY, Ana KRTOLICA, Natacha LE MOAN, Jonathan A. WINGER, Kevin G. LEONG
-
Publication number: 20170267732Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: October 12, 2016Publication date: September 21, 2017Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Emily WEINERT, Jonathan A. WINGER, Michael A. MARLETTA
-
Patent number: 9493527Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: GrantFiled: September 18, 2014Date of Patent: November 15, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Jonathan A. Winger, Michael A. Marletta
-
Patent number: 9493526Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: September 17, 2014Date of Patent: November 15, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20150376250Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: September 17, 2014Publication date: December 31, 2015Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Emily WEINERT, Jonathan A. WINGER, Michael A. MARLETTA
-
Publication number: 20150266931Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: ApplicationFiled: September 18, 2014Publication date: September 24, 2015Inventors: STEPHEN P. L. CARY, ELIZABETH M. BOON, JONATHAN A. WINGER, MICHAEL A. MARLETTA
-
Publication number: 20130289252Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: ApplicationFiled: February 20, 2013Publication date: October 31, 2013Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Jonathan A. WINGER, Michael A. MARLETTA
-
Patent number: 8404632Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: GrantFiled: May 21, 2007Date of Patent: March 26, 2013Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Jonathan A. Winger, Michael A. Marletta
-
Patent number: 8404631Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: GrantFiled: May 21, 2007Date of Patent: March 26, 2013Assignee: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20100285104Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.Type: ApplicationFiled: May 21, 2007Publication date: November 11, 2010Applicant: The Regents of the University of CaliforniaInventors: Stephen P. L. Cary, Elizabeth M. Boon, Emily Weinert, Jonathan A. Winger, Michael A. Marletta
-
Publication number: 20100266673Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or 02 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.Type: ApplicationFiled: May 21, 2007Publication date: October 21, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Stephen P. L. Cary, Elizabeth M. Boon, Jonathan A. Winger, Michael A. Marletta